Identification of novel anti-persister activity against Borrelia burgdorferi from an FDA-approved drug library

Written by Global Lyme Alliance | Feb 19, 2014 4:46:08 AM

A library of drug compounds that has already been approved by the FDA was tested for efficacy against persister forms of Borrelia burgdorferi that were grown in lab culture. They identified daptomycin, clofazimine, sulfa drugs, and cefoperazone as potential drugs worth pursuing in further studies, which may include animal models of Lyme disease.